Vir Biotechnology Inc. Common Stock (VIR)
Stock · NASDAQ · Health Care
$10.83as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$9.12
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Fundamentals
- Market cap
- $1.50B
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
How Vir Biotechnology Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 23, 2026 · via SEC EDGAR / Finnhub
Vir Biotechnology Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VIRVir Biotechnology Inc. Common Stock$10.83▼ 4.24%Market cap $1.50BP/E —
- RXRXRecursion Pharmaceuticals Inc. Class A Common Stock$3.33▼ 3.20%Market cap $1.69BP/E —$2.77$7.18
- GLUEMonte Rosa Therapeutics Inc. Common Stock$13.37▼ 6.63%Market cap $1.30BP/E —$4.6$25.77
- INBXInhibrx Biosciences Inc. Common Stock$123.93▼ 0.00%Market cap $1.21BP/E —$26.19$155.29
- IMTXImmatics N.V. Ordinary Shares$9.45▲ 0.91%Market cap $1.21BP/E —$5.05$12.41
- VORVor Biopharma Inc. Common Stock$22.66▼ 3.70%Market cap $1.16BP/E —$6.5$49.95
- MESOMesoblast Limited American Depositary Shares$17.42▼ 4.18%Market cap $1.87BP/E —$1.88$3.31
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VIR Vir Biotechnology Inc. Common Stock | $1.50B | — | $10.83 | ▼ 4.24% | |
| RXRX Recursion Pharmaceuticals Inc. Class A Common Stock | $1.69B | — | $3.33 | ▼ 3.20% | $2.77$7.18 |
| GLUE Monte Rosa Therapeutics Inc. Common Stock | $1.30B | — | $13.37 | ▼ 6.63% | $4.6$25.77 |
| INBX Inhibrx Biosciences Inc. Common Stock | $1.21B | — | $123.93 | ▼ 0.00% | $26.19$155.29 |
| IMTX Immatics N.V. Ordinary Shares | $1.21B | — | $9.45 | ▲ 0.91% | $5.05$12.41 |
| VOR Vor Biopharma Inc. Common Stock | $1.16B | — | $22.66 | ▼ 3.70% | $6.5$49.95 |
| MESO Mesoblast Limited American Depositary Shares | $1.87B | — | $17.42 | ▼ 4.18% | $1.88$3.31 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call TranscriptSeekingAlpha · 8/6/2026
- Vir Biotechnology (NASDAQ:VIR) Jumps 10% on Q2 Beat and Astellas CollaborationChartMill · 8/6/2026
- Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M EstimateBenzinga · 8/5/2026
Insider Activity
Insider Actions →Acquired
144.0K
Disposed
11.6K
- Robert J. More · August 11, 2026 · J8.0K
- Timothy Coughlin · June 9, 2026 · Grant16.0K
- Timothy Coughlin · June 9, 2026 · Grant8.0K
- Janet Napolitano · June 1, 2026 · Sale3.2K @ $9.45
- Brent Sabatini · June 1, 2026 · Sale379 @ $9.45
- Janet Napolitano · May 27, 2026 · Grant16.0K
- Janet Napolitano · May 27, 2026 · Grant8.0K
- Ramy Farid · May 27, 2026 · Grant16.0K
- Ramy Farid · May 27, 2026 · Grant8.0K
- Charles Elliott Sigal · May 27, 2026 · Grant16.0K
- Charles Elliott Sigal · May 27, 2026 · Grant8.0K
- Jeffrey S. Hatfield · May 27, 2026 · Grant16.0K
- Jeffrey S. Hatfield · May 27, 2026 · Grant8.0K
- Robert J. More · May 27, 2026 · Grant16.0K
- Robert J. More · May 27, 2026 · Grant8.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 128.70M
- Total value held
- $1.14B
- Institutional holders
- 247
Top holders this quarter
- Unknown18.00M
- Unknown12.92M
- Unknown10.95M
- Unknown8.55M
- Unknown7.14M
- Unknown5.38M
- Unknown3.25M
- Unknown2.85M
- Unknown2.74M
- Unknown2.66M
See the full, filterable feed with live charts on the MarketWall dashboard.